GSK Oncology Pipeline Expansion Means Healthy Phase III Program In ’06

GlaxoSmithKline's strategy of building its oncology business is paying off with a range of new chemical entities entering Phase III development within the next year for cancer-related indications, executives said during an oncology R&D update in New York

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet